Pharvaris N.V. (PHVS) is a late-stage, clinical-stage biopharmaceutical company based in Leiden, the Netherlands, developing oral bradykinin B2-receptor antagonists for hereditary angioedema and related rare diseases. Because it is pre-revenue, its valuation rests almost entirely on the clinical and regulatory outlook for its lead asset, deucrictibant.
The $60 central target reflects roughly 14 verified, current analyst price targets. The underlying arithmetic mean is approximately $61, rounded to $60 for readability. The range is unusually wide, from about $44 at the low end (Guggenheim and Bank of America) to $79 at the high end (Citizens JMP), with most targets clustered in the $50 to $65 zone. Recent actions include Wells Fargo at $65, Morgan Stanley at $62, RBC Capital at $62, Cantor Fitzgerald and Leerink Partners at $65, H.C. Wainwright at $60, and Wedbush at $50. Bank of America upgraded the shares to Buy with a $44 target in late October 2026.
The wide spread reflects genuine analytical disagreement: bullish analysts emphasize deucrictibant's oral convenience and positive Phase 3 results, while cautious analysts weigh execution, regulatory, and competitive risk. This figure is a calculated average, not an official published consensus, and it is not a guarantee of future performance.
Shares of PHVS trade near $34, within a 52-week range of roughly $21 to $43. Reaching the $60 average analyst price target would require upside of approximately 76%, which qualifies as a very large move. The stock rallied strongly in mid-2026 on positive Phase 3 data but has since pulled back from its highs near $43.
The path toward $60 would likely depend on continued positive clinical readouts, a successful regulatory filing, and eventual U.S. Food and Drug Administration (FDA) approval of deucrictibant. As a clinical-stage company with no product revenue and a reported net loss, Pharvaris' valuation is driven by milestones rather than current earnings, so the move would need to be justified by de-risking of the pipeline rather than near-term fundamentals.
The central catalyst is deucrictibant, being developed as both an immediate-release capsule (PHVS416) for on-demand HAE attack treatment and an extended-release tablet (PHVS719) for prophylaxis. Positive Phase 3 RAPIDe-3 results for the immediate-release formulation, along with Phase 3 data showing the extended-release formulation substantially reduced HAE attack rates, drove the September 2026 wave of analyst target increases.
An oral therapy offers meaningful convenience relative to injectable HAE treatments, a differentiator analysts have highlighted. A strong cash position supports development through key milestones, and broadly bullish ratings (nearly all covering analysts rate the stock Buy or equivalent) reflect a favorable professional view of the risk-reward. A potential regulatory submission and eventual approval decision represent additional de-risking events that could support a higher valuation.
Pharvaris remains pre-revenue with ongoing losses and cash burn, so execution risk is material. Regulatory review can delay or derail approval, and clinical data, however promising, is not a guarantee of commercial success. The HAE market is competitive, including oral options such as BioCryst's (BCRX) Orladeyo and injectable therapies from larger players, which could pressure pricing and market share.
Additionally, the shares trade on expectations rather than earnings, leaving them vulnerable to valuation compression if sentiment shifts. Further share issuance to fund operations could dilute existing holders, and the wide analyst target range signals that some professionals see substantially less upside than the average implies.
The 52-week high near $43 represents a meaningful resistance zone, as the stock has already reversed from that area once. The $40 round-number level and the prior peak near $43 are the clearest overhead markers on the way toward $60. On the downside, the low-$30s area near the current price and the 52-week low near $21 mark key support levels. The stock's pullback of roughly 20% from its 52-week high shows how quickly sentiment-driven biotech moves can reverse.
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact period varies by firm and is rarely stated explicitly. Investors should watch upcoming clinical data readouts, the timing and acceptance of any regulatory submission for deucrictibant, and guidance on cash runway and financing plans. Analyst rating and target revisions, insider transactions, and competitive developments in the HAE space will also be important. Regulatory decisions, once a filing is made, represent the single most consequential near-term catalyst.
For traders seeking a more dynamic view, Tickeron's AI Daily Buy/Sell Signals offer a technology-driven complement to traditional analyst research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting trends more efficiently than manual screening allows. Investors following PHVS may find this an efficient way to track evolving momentum alongside the fundamental picture.
The question of whether Pharvaris can reach $60 ultimately rests on execution across clinical, regulatory, and eventually commercial milestones rather than any near-term earnings trajectory. The $60 figure is a calculated average of roughly 14 analyst targets spanning $44 to $79, requiring a very large gain of about 76% from the current price near $34. Support comes from encouraging Phase 3 data and an oral-dosing advantage, while the principal obstacles are regulatory risk, a pre-revenue profile with ongoing cash burn, and a competitive HAE market. With analysts disagreeing widely on fair value, investors should focus on the next data readouts, the regulatory filing path, and revisions to analyst expectations rather than treating the average target as a forecast or a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PHVS has been loosely correlated with IMNM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PHVS jumps, then IMNM could also see price increases.
| Ticker / NAME | Correlation To PHVS | 1D Price Change % | ||
|---|---|---|---|---|
| PHVS | 100% | +0.56% | ||
| IMNM - PHVS | 46% Loosely correlated | +2.25% | ||
| SYRE - PHVS | 46% Loosely correlated | +2.24% | ||
| SVRA - PHVS | 42% Loosely correlated | +1.42% | ||
| MGTX - PHVS | 41% Loosely correlated | +0.62% | ||
| ROIV - PHVS | 40% Loosely correlated | +1.60% | ||
More | ||||